AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7595735
Drug: FAM2 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAM2 regimen (fluorouracil [5‐FU], doxorubicin, and mitomycin) administered every 43 days for seven cycles.
Trial: 6968855
Drug: Electrolyte solution
RxNorm normalized name: electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte solution with magnesium (MgKCP)
Trial: 20930165
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no aspirin treatment)
Trial: 9949940
Drug: buspirone (15‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buspirone (15‐20 mg/d)
Trial: 9817192
Drug: Amlodipine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5-10 mg once daily)
Trial: 381073
Drug: Anti-rabies human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-rabies human diploid cell vaccine (HDCV)
Trial: 25569817
Drug: Alfacalcidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (1 μg/d) alone
Trial: 25569817
Drug: Alfacalcidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (1 μg/d) and raloxifene hydrochloride (60 mg/d)
Trial: 11386488
Drug: Citalopram (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (7 days treatment)
Trial: 11677866
Drug: Bisoprolol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol treatment
Trial: 2668252
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg bd
Trial: 23731101
Drug: Asthma clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asthma clinic intervention providing education, self-monitoring promotion, regular treatment review, and written asthma action plan
Trial: 22126164
Drug: Detailed information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detailed information on morphine (experimental group)
Trial: 31548595
Drug: Capsule (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule (3000 IU/day)
Trial: 31548595
Drug: Sublingual spray
RxNorm normalized name: Myoden, sublingual spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual spray (3000 IU/day)
Trial: 15583924
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT)
Trial: 18677970
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of triflusal (600 mg)
Trial: 18677970
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of triflusal (600 mg)
Trial: 16208839
Drug: Modafinil (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100-400 mg) as augmentation to ongoing antidepressant therapy
Trial: 16208839
Drug: Modafinil (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100-400 mg)
Trial: 12072038
Drug: Oral soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral soy isoflavone concentrate containing 80 mg of soy isoflavones
Trial: 10590004
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac tromethamine 0.5% ophthalmic solution (Acular)
Trial: 6882984
Drug: Treatment-resistant patients
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-resistant patients after real ECT
Trial: 30568305
Drug: Personalized neoantigen-targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized neoantigen-targeting vaccines
Trial: 26387494
Drug: Peginterferon alpha-2b
RxNorm normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alpha-2b monotherapy
Trial: 24465022
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sham injection)
Trial: 18978495
Drug: High-dose apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose apomorphine (APO)
Trial: 18978495
Drug: Low-dose apomorphine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose apomorphine (APO)
Trial: 2624401
Drug: Endoscopic laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic laser therapy
Trial: 26527790
Drug: Lapatinib (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1,500 mg per day) during chemoradiotherapy and as maintenance monotherapy for 12 months
Trial: 15330327
Drug: Granulocyte-colony stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony stimulating factor (G‐CSF) 5 microg/kg body weight per day subcutaneously
Trial: 8098222
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g carbohydrate from flaxseed or 25 g flaxseed mucilage
Trial: 8098222
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g flaxseed oil or flour/kg in muffins
Trial: 8098222
Drug: 150 g
RxNorm normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 g flaxseed/kg in baked muffins
Trial: 2436002
Drug: Cilazapril 30
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 30 mg
Trial: 10424316
Drug: Captopril 12.5
RxNorm normalized name: captopril 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.5 mg
Trial: 314724
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (bypass surgery)
Trial: 26645256
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (nonsurgical)
Trial: 21395104
Drug: Low-calorie dietary
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie dietary supplement containing a small amount of carbohydrates and fats
Trial: 15933556
Drug: Pamphlet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamphlet and videotape promoting judicious use of antibiotics
Trial: 8969668
Drug: Drainage with
RxNorm normalized name: BAG,AEROSOL DRAINAGE WITH Y CONNECTOR #HSK974Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drainage with concurrent fistulotomy
Trial: 7511740
Drug: lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lisinopril
Trial: 1315483
Drug: lisinopril and
RxNorm normalized name: lisinopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril and isradipine (combined)
Trial: 27285928
Drug: Arg administration
RxNorm normalized name: Arg
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arg administration (345 μmol Arg HCl/kg BW, 3 times per day)
Trial: 27285928
Drug: Arg administration
RxNorm normalized name: Arg
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arg administration
Trial: 25878028
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (50 μg, 100 μg, or 200 μg) plus vilanterol (25 μg)
Trial: 25007003
Drug: Quetiapine-XR (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine-XR (mean dose 276 +/- 50 mg/d, range 50-300 mg/d)
Trial: 23103305
Drug: Acute lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute lorazepam (2 mg orally)
Trial: 20735783
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg bid for 12 weeks
Trial: 31206210
Drug: mCTAR exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mCTAR exercise and traditional dysphagia treatment
Trial: 20197019
Drug: Test oral
RxNorm normalized name: Femtest Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test oral suspension of nimesulide 50 mg/ml
Trial: 20197019
Drug: Nisulid 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisulid 100 mg tablet
Trial: 19223674
Drug: Sodium‐citrate plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium‐citrate plus Gatorade (NaCIT: 170 mmol Na+L(‐1))
Trial: 12453280
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL Stronger Neo-Minophagen C (SNMC) administered three times a week for 12 weeks
Trial: 12453280
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL Stronger Neo-Minophagen C (SNMC) administered three times a week for 12 weeks
Trial: 10357743
Drug: Calcium glycerophosphate-supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium glycerophosphate-supplemented infant formula (1800 mg Ca and 1390 mg P/L)
Trial: 10357743
Drug: Iron-fortified infant
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified infant formula (465 mg Ca and 317 mg P/L)
Trial: 2166429
Drug: Ketoconazole (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (600 mg/day for 28 days)
Trial: 2166429
Drug: Pentostam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentostam (20 mg antimony/kg for 20 days)
Trial: 7197583
Drug: Cisplatin 30
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 30 mg/m2/week
Trial: 31565909
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation with individualized dosing to achieve 25(OH)D of 120 nmol/L for 8 weeks
Trial: 31210099
Drug: Ciclosporin (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin (initial loading dose of 2.5 mg/kg followed by continuous infusion for 5 days; first 10 patients received 5 mg/kg/day, subsequent 6 patients received 10 mg/kg/day)
Trial: 11583199
Drug: Amifostine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (500 mg per day during conventional-dose TIP and two doses of 500 mg during high-dose CET)
Trial: 7990309
Drug: Endobronchial application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial application of a helium-neon laser beam in combination with traditional methods in the preoperative period
Trial: 25976288
Drug: Control (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (six weekly sessions of behavioural support for smoking cessation)
Trial: 8156739
Drug: Ethanol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.5 g body weight/kg)
Trial: 8156739
Drug: Ethanol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (1.0 g body weight/kg)
Trial: 3345153
Drug: 0.5% ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ketorolac tromethamine solution
Trial: 29222647
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg every 3 weeks plus chemotherapy (cisplatin 50 mg/m2 or carboplatin AUC 5 plus paclitaxel 175 mg/m2 for 6-8 cycles)
Trial: 21915047
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of bevacizumab 2 mg (1 mg/0.04 mL)
Trial: 21915047
Drug: Topical antihistamine
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antihistamine (antazoline HCl 0.05%) and vasoconstrictor (tetrahydrozoline HCl 0.04%)
Trial: 12869833
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor (PI)-based regimen
Trial: 10516747
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral idarubicin (ZAVEDOS-ZVD) 20 mg/m2 on days 1, 8, 15, and 22 for induction; 20 mg/m2 for 4 weeks for consolidation; maintenance with oral 6 mercaptopurine 2 mg/kg/day, subcutaneous cytarabine 1 mg/kg, and oral ZVD 20 mg/m2 on day 1 and day 8 of the third month.
Trial: 10516747
Drug: Salvage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage treatment with 4 weekly oral doses of 40 mg/m2 ZVD after induction failure.
Trial: 10516747
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with weekly oral idarubicin (ZAVEDOS-ZVD) 20 mg/m2.
Trial: 14607696
Drug: Endoscopic retrograde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic retrograde cholangiopancreatography (ERCP) within 24 hours after admission, combined with supportive treatment and traditional Chinese medicine.
Trial: 14607696
Drug: Non-ERCP treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ERCP treatment, combined with supportive treatment and traditional Chinese medicine.
Trial: 14607696
Drug: ERCP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERCP treatment in mild acute GP patients.
Trial: 3658278
Drug: Cefazolin (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1-g dose)
Trial: 3658278
Drug: Cefonicid (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid (1-g dose)
Trial: 29780106
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of oral medications
Trial: 29780106
Drug: Drug burden
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug burden comparison
Trial: 17075122
Drug: Bortezomib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.5 mg/m2 (arm A)
Trial: 11185632
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg three times daily
Trial: 9457396
Drug: DLI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLI plus low-dose rIL-2
Trial: 9457396
Drug: High-dose rIL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rIL-2
Trial: 9457396
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rIL-2 and IFN-alpha
Trial: 7897617
Drug: Amisulpride 20
RxNorm normalized name: amisulpride 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride 20 mg
Trial: 9226734
Drug: Amisulpride 100
RxNorm normalized name: amisulpride 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride 100 mg
Trial: 3310792
Drug: Air-fluidized beds
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air-fluidized beds (Clinitron Therapy)
Trial: 31765277
Drug: Technology-enhanced reading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology-enhanced reading therapy (14 hours)
Trial: 31765277
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (delayed therapy)
Trial: 29855167
Drug: Supraciliary implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraciliary implantation of hema implant (Esnoper V-2000)
Trial: 29855167
Drug: Intrascleral implantation
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intrascleral implantation of hema implant (Esnoper V-2000)
Trial: 26579985
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (first-line therapy failure).
Trial: 11360565
Drug: Traditional medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional medicine Syndrome Differentiation
Trial: 15957828
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medicine alone
Trial: 27083449
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch for 6 weeks
Trial: 20378736
Drug: MDMA (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (1.6 mg/kg)
Trial: 10458207
Drug: Docetaxel in
RxNorm normalized name: docetaxel Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel in combination with gemcitabine
Trial: 10458207
Drug: Docetaxel within
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel within a sequential and concomitant chemoradiotherapy concept
Trial: 2037789
Drug: B subunit
RxNorm normalized name: Modified Cholera toxin B subunit
DrugBank: Modified Cholera toxin B subunit (DB18557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B subunit (BS)‐whole‐cell vaccine
Trial: 19842576
Drug: Treatment modalities
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment modalities for psoriasis (exact treatments not specified) for 15 participants over 16 weeks followed by 12 weeks of observation.
Trial: 15521902
Drug: Methadone 5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 5‐20 mg 12 hourly
Trial: 15521902
Drug: Tincture of
RxNorm normalized name: Tincture of opium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tincture of opium (TOP) 3.33‐10 mg morphine equivalents 12 hourly
Trial: 8839906
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tropisetron
Trial: 12183788
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tropisetron
Trial: 7839305
Drug: Control (motility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (motility modifying drugs)
Trial: 356971
Drug: Combination or
RxNorm normalized name: PROBIOTIC COMBINATION ORAL CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination or single-agent therapy with methyl-CCNU, vinblastine, and medroxyprogesterone
Trial: 23452506
Drug: Adherence Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence Therapy (AT)
Trial: 18997461
Drug: TFA-enriched diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFA-enriched diet (10.4 g TFAs for 4 days)
Trial: 18997461
Drug: Standard diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diet (0.8 g TFAs)
Trial: 16014054
Drug: High CRP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CRP (≥3.0 mg/L)
Trial: 1341478
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with corticoids (40 mg/day for 2 weeks, then 20 mg/day for 2 weeks) followed by interferon-alpha (2 MU, 3 times a week for 3 months)
Trial: 26765505
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care protocol (tooth brushing, tongue scraping, flossing, mouth rinsing, lip care)
Trial: 31572763
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care protocol
Trial: 18827631
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion pump with Bupivacaine (0.375%)
Trial: 10919936
Drug: Salt-restricted diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt-restricted diet (<5 g/d sodium chloride)
Trial: 8670579
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 250 mg monthly injections
Trial: 1522491
Drug: Sustained-release hydralazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release hydralazine without KCl
Trial: 30753272
Drug: cediranib 30
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cediranib 30 mg daily and olaparib capsules 200 mg twice daily
Trial: 30753272
Drug: olaparib capsules
RxNorm normalized name: Olaparib Capsules
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: olaparib capsules 400 mg twice daily
Trial: 30753272
Drug: cediranib/olaparib combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cediranib/olaparib combination in gBRCA wild-type/unknown patients
Trial: 30753272
Drug: cediranib/olaparib combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cediranib/olaparib combination in gBRCAm patients
Trial: 29428785
Drug: Iron-folic acid
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-folic acid supplements
Trial: 17255882
Drug: HES 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 130/0.4 (Group H, 45 g/d), HES 130/0.4 (Group M, 30 g/d), HES 130/0.4 (Group L, 15 g/d)
Trial: 17255882
Drug: Glucose 5%
RxNorm normalized name: Glucose 5% Nursette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 5% (Group G)
Trial: 12141616
Drug: Current smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current smoking (25 or more cigarettes daily)